Your browser doesn't support javascript.
loading
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Chen, Kuei-Ting; Madison, Russell; Moore, Jay; Jin, Dexter; Fleischmann, Zoe; Newberg, Justin; Schrock, Alexa; Bhardwaj, Neeru; Lofgren, Katherine T; He, Jie; Frampton, Garrett; Hegde, Priti; Fabrizio, David; Pishvaian, Michael J; Ebot, Ericka; Singhi, Aatur; Sokol, Ethan.
  • Chen KT; Foundation Medicine, Cambridge, MA, USA.
  • Madison R; Foundation Medicine, Cambridge, MA, USA.
  • Moore J; Foundation Medicine, Cambridge, MA, USA.
  • Jin D; Foundation Medicine, Cambridge, MA, USA.
  • Fleischmann Z; Foundation Medicine, Cambridge, MA, USA.
  • Newberg J; Foundation Medicine, Cambridge, MA, USA.
  • Schrock A; Foundation Medicine, Cambridge, MA, USA.
  • Bhardwaj N; Foundation Medicine, Cambridge, MA, USA.
  • Lofgren KT; Foundation Medicine, Cambridge, MA, USA.
  • He J; Foundation Medicine, Cambridge, MA, USA.
  • Frampton G; Foundation Medicine, Cambridge, MA, USA.
  • Hegde P; Foundation Medicine, Cambridge, MA, USA.
  • Fabrizio D; Foundation Medicine, Cambridge, MA, USA.
  • Pishvaian MJ; Department of Oncology, Johns Hopkins University School of Medicine, SKCC, Washington, DC, USA.
  • Ebot E; Foundation Medicine, Cambridge, MA, USA.
  • Singhi A; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Sokol E; Foundation Medicine, Cambridge, MA, USA.
Oncologist ; 28(8): 691-698, 2023 08 03.
Article en En | MEDLINE | ID: mdl-37354528

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article